1-3 of 3
Cristina Livideanu
Close
Sort by
Journal Articles

Omalizumab: Efficacy and Safety in Mast Cell Disorders

Richard Lemal, MD, Guillemette Fouquet, Louis Terriou, MD, Mélanie Vaes, MD, Cristina Livideanu, MD, Laurent Frenzel, MD PhD, Stéphane Barete, Danielle Canioni, MD, Ludovic Lhermitte, MD PhD, Jacques-Olivier Bay, MD PhD, Julien Rossignol, MD PhD, Michel Arock, Olivier Lortholary, Olivier Hermine, MD PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 4280.
https://doi.org/10.1182/blood-2018-99-114739
Published: 2018
Journal Articles

In aggressive forms of mastocytosis, TET2 loss cooperates with c-KITD816V to transform mast cells

Brief Report
Erinn Soucie, Katia Hanssens, Thomas Mercher, Sophie Georgin-Lavialle, Gandhi Damaj, Cristina Livideanu, Maria Olivia Chandesris, Yolène Acin, Sebastien Létard, Paulo de Sepulveda, Olivier Hermine, Olivier A. Bernard, Patrice Dubreuil
Journal: Blood
Blood (2012) 120 (24): 4846–4849.
https://doi.org/10.1182/blood-2011-12-397588
Published: 2012
Includes: Supplemental data
Journal Articles

Thalidomide in Advanced Mastocytosis. Results from an Open-Label, Multicentric, Phase II Study

Berengere Gruson, Olivier Lortholary, MD, PhD, Danielle Canioni, marie-Olivia Chandesris, Fanny Lanternier, Bernard Grosbois, Sr., MD, Cristina Livideanu, MD, Thierry Lamy, MD, PhD, Henri Sevestre, MD, PhD, Claire Larroche, MD, Aurélie Esparcieux, MD, Guillaume Chaby, MD, Jean Pierre Marolleau, MD, Olivier Hermine, MD, PhD, Gandhi Damaj, MD
Journal: Blood
Blood (2011) 118 (21): 1754.
https://doi.org/10.1182/blood.V118.21.1754.1754
Published: 2011